Investing in Stocks Made Easy!
at ₹0 Brokerage with 5paisa.
+91
By proceeding, you agree to all T&C*
Investing in Stocks Made Easy!
We've sent a 6-digit verification code to +91 99123918232
Didn't receive the code? Resend
VINEETLAB

Vineet Laboratories Share Price

 

 

Vineet Laboratories live price: ₹34.8. It opened at ₹35 vs previous close ₹34; intraday high/low: ₹35/₹33. The 50 & 200 DMA stand at ₹34.73/₹33.78.

Vineet Laboratories Performance

  • Today's Low
  • ₹33
  • Today's High
  • ₹35
  • 52 Week Low
  • ₹24
  • 52 Week High
  • ₹44
  • Open Price₹35
  • Previous Close₹34
  • Volume26,164
  • 50 DMA₹34.73
  • 100 DMA₹34.02
  • 200 DMA₹33.78

Vineet Laboratories Chart

Investment Returns

  • Over 1 Month -8.57%
  • Over 3 Month + 17.85%
  • Over 6 Month -4.21%
  • Over 1 Year + 30.43%

Smart Investing Starts Here Start SIP with Vineet Laboratories for Steady Growth!

Invest Now

Vineet Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -6.6
  • PEG Ratio
  • 0.2
  • Market Cap Cr
  • 67
  • P/B Ratio
  • 2.7
  • Average True Range
  • 1.94
  • EPS
  • 0
  • Dividend Yield
  • 0
  • MACD Signal
  • 0.06
  • RSI
  • 46
  • MFI
  • 33.57

Vineet Laboratories Financials

Vineet Laboratories Technicals

EMA & SMA

Current Price
₹34.80
+ 0.53 (1.55%)
pointer
  • Bearish Moving Average 6
  • Bullish Moving Average 10
  • 20 Day
  • ₹35.30
  • 50 Day
  • ₹34.73
  • 100 Day
  • ₹34.02
  • 200 Day
  • ₹33.78

Resistance and Support

34.09 Pivot Speed
  • R3 36.83
  • R2 35.86
  • R1 35.06
  • S1 33.29
  • S2 32.32
  • S3 31.52

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Vineet Laboratories has an operating revenue of Rs. 54.59 Cr. on a trailing 12-month basis. An annual revenue de-growth of -49% needs improvement, Pre-tax margin of -28% needs improvement, ROE of -137% is poor and needs improvement. The company has a reasonable debt to equity of 26%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its key moving averages, around -0% and 2% from 50DMA and 200DMA. It needs to stay above these levels to make any further meaningful move. It has recently broken out of a base in its weekly chart but failed to keep its momentum and is trading around -18% from the pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 63 which is a FAIR score but needs to improve its earnings, a RS Rating of 79 which is FAIR indicating the recent price performance, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 64 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Vineet Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-14 Quarterly Results
2025-11-27 Right issue of Equity Shares
2025-11-08 Quarterly Results
2025-07-22 Quarterly Results
2025-05-12 Audited Results
Date Purpose Remarks
2022-09-20 FINAL Rs.1.00 per share(10%)Final Dividend
View Vineet Laboratories Dividend History Arrow

Vineet Laboratories Shareholding Pattern

5.98%
0.36%
88.74%
4.92%

Vineet Laboratories FAQs

Vineet Laboratories share price is ₹34 As on 02 June, 2026 | 17:33

The Market Cap of Vineet Laboratories is ₹66.8 Cr As on 02 June, 2026 | 17:33

The P/E ratio of Vineet Laboratories is -6.6 As on 02 June, 2026 | 17:33

The PB ratio of Vineet Laboratories is 2.7 As on 02 June, 2026 | 17:33

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23